Cover Image
市場調查報告書

AnGes MG, Inc.的產品平台分析

AnGes MG, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 259349
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
AnGes MG, Inc.的產品平台分析 AnGes MG, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 43 Pages
簡介

AnGes MG, Inc. 是致力於發現及研發遺傳基因療法功能分析用之遺傳基因及核苷酸基礎藥劑的生物製藥公司。該公司致力於遺傳醫學的研究開發與實用上的應用,再生血管改善血流的遺傳藥及異位性皮膚炎治療藥oligo核苷酸是其二大代表產品。

本報告提供AnGes MG, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

AnGes MG, Inc.的基本資料

  • AnGes MG, Inc.概要
  • 主要資訊
  • 企業資料

AnGes MG, Inc.:R&D概要

  • 主要的治療範圍

AnGes MG, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

AnGes MG, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

AnGes MG, Inc.:藥物簡介

  • beperminogene perplasmid
  • velimogene aliplasmid
  • S-414114
  • GEN-0101
  • AG-30/5C

AnGes MG, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AnGes MG, Inc.:最近的開發平台趨勢

AnGes MG, Inc.:暫停中的計劃

AnGes MG, Inc.:企業發表

AnGes MG, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06867CDB

Summary

Global Markets Direct's, 'AnGes MG, Inc. - Product Pipeline Review - 2015', provides an overview of the AnGes MG, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AnGes MG, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of AnGes MG, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AnGes MG, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AnGes MG, Inc.'s pipeline products

Reasons to buy

  • Evaluate AnGes MG, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AnGes MG, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AnGes MG, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AnGes MG, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AnGes MG, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AnGes MG, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AnGes MG, Inc. Snapshot
    • AnGes MG, Inc. Overview
    • Key Information
    • Key Facts
  • AnGes MG, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • AnGes MG, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • AnGes MG, Inc. - Pipeline Products Glance
    • AnGes MG, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • AnGes MG, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • AnGes MG, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AnGes MG, Inc. - Drug Profiles
    • beperminogene perplasmid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • velimogene aliplasmid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-414114
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-30/5C
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody for Ebola Virus Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AnGes MG, Inc. - Pipeline Analysis
    • AnGes MG, Inc. - Pipeline Products by Target
    • AnGes MG, Inc. - Pipeline Products by Route of Administration
    • AnGes MG, Inc. - Pipeline Products by Molecule Type
    • AnGes MG, Inc. - Pipeline Products by Mechanism of Action
  • AnGes MG, Inc. - Recent Pipeline Updates
  • AnGes MG, Inc. - Dormant Projects
  • AnGes MG, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • S-414114
  • AnGes MG, Inc. - Company Statement
  • AnGes MG, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AnGes MG, Inc., Key Information
  • AnGes MG, Inc., Key Facts
  • AnGes MG, Inc. - Pipeline by Indication, 2015
  • AnGes MG, Inc. - Pipeline by Stage of Development, 2015
  • AnGes MG, Inc. - Monotherapy Products in Pipeline, 2015
  • AnGes MG, Inc. - Partnered Products in Pipeline, 2015
  • AnGes MG, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • AnGes MG, Inc. - Phase III, 2015
  • AnGes MG, Inc. - Phase II, 2015
  • AnGes MG, Inc. - Phase I, 2015
  • AnGes MG, Inc. - Preclinical, 2015
  • AnGes MG, Inc. - Discovery, 2015
  • AnGes MG, Inc. - Pipeline by Target, 2015
  • AnGes MG, Inc. - Pipeline by Route of Administration, 2015
  • AnGes MG, Inc. - Pipeline by Molecule Type, 2015
  • AnGes MG, Inc. - Pipeline Products by Mechanism of Action, 2015
  • AnGes MG, Inc. - Recent Pipeline Updates, 2015
  • AnGes MG, Inc. - Dormant Developmental Projects,2015
  • AnGes MG, Inc. - Discontinued Pipeline Products, 2015
  • AnGes MG, Inc., Other Locations
  • AnGes MG, Inc., Subsidiaries

List of Figures

  • AnGes MG, Inc. - Pipeline by Top 10 Indication, 2015
  • AnGes MG, Inc. - Pipeline by Stage of Development, 2015
  • AnGes MG, Inc. - Monotherapy Products in Pipeline, 2015
  • AnGes MG, Inc. - Pipeline by Top 10 Target, 2015
  • AnGes MG, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • AnGes MG, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • AnGes MG, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top